Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Fosdesdenosine Sipalabenamide · NUC-7738

Small molecule

Phase 1/2 Most advanced trial
1 Registered trials

What is Fosdesdenosine Sipalabenamide?

Fosdesdenosine sipalabenamide is a phosphoramidate prodrug of the monophosphate form of cordycepin (3'-deoxyadenosine). After cellular uptake it is converted to 3'-deoxyadenosine triphosphate, which competes with ATP during transcription, inhibits RNA synthesis and induces apoptosis. It is studied in advanced cancer, lymphoma, solid tumors and melanoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
NUC-7738, Nucleotide Analogue
Drug type
Small molecule
Pathways
RNA synthesis inhibition, apoptosis, AMPK activation, PI3K/AKT/mTOR signaling
Therapy area
Oncology
In trials of
NCNA
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
Y7BFN2M72F

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03829254 Phase 1/2 Advanced Cancer Recruiting NCNA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced CancerLymphomaMelanomaSolid Tumor

Sources

Updated Oct 25, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.